

GLUT-targeting multivalent iminoglyco-NPs with potential theranostic application

Francesca Milano¹, Camilla Matassini¹, Alessandra Quarta², Francesca Cardona¹, Andrea Ragusa^{2,3}, Andrea Goti¹ and Marco Marradi¹

¹*Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy*

²*CNR-Nanotec, Institute of Nanotechnology, Via Monteroni, 73100 Lecce, Italy*

³*Department of Biological and Environmental Sciences and Technologies, Campus Ecotekne, University of Salento, Via Monteroni, 73100 Lecce, Italy*

E-mail: francesca.milano@unifi.it

Gaucher's disease (GD) is a rare autosomal recessive disease caused by a deficiency in the activity of the glucocerebrosidase (GCase) enzyme due to mutations in the GBA gene. Studies show that GBA genetic mutations are also a risk factor for Parkinson's disease, suggesting that therapeutic approaches to modulate GCase activity could play an important role in treating both diseases [1]. An innovative therapeutic strategy for the treatment of GD is the use of pharmacological chaperones (PCs) to enhance natural enzymatic activity, although currently no PC has yet reached the market for this pathology. Iminosugars and other substrate analogues acting as competitive inhibitors of GCase are promising candidates as PCs [2]. As the blood brain barrier (BBB) represents an obstacle for the classical enzyme replacement treatment of neuronopathic forms of GD, the synthesis of novel iminosugars functionalized with specific ligands able to enhance the transport through the BBB is being investigated. In addition, since a greater affinity between enzyme and multivalent iminosugars has been demonstrated, the multimerization of the iminosugars onto nanoparticles (NPs) will be carried out to combine the properties of the inhibitors to the multivalency of the NPs, thus yielding smart systems with theranostic properties [3].

References

1. Riboldi, G.M., Di Fonzio, A.B. *Cells* **2019**, 8, 364;
2. Compain, P., Martin, O.R., Boucheron, C., Godin, G., Yu, L., Ikeda, K., Asano, N. *ChemBioChem* **2020**, 1, 10;
3. Malvindi, M.A., Di Corato, R., Curcio, A., Melisi, D., Rimoli, M.G., Tortiglione, C., Tino, A., George, C., Brunetti, V., Cingolani, R., Pellegrino, T., Ragusa, A. *Nanoscale* **2011**, 3, 5110.

We acknowledge the support of the European Union by the Next Generation EU project ECS00000017 'Ecosistema dell'Innovazione' Tuscany Health Ecosystem (THE, PNRR, Spoke 4: Nanotechnologies for diagnosis and therapy).